Wells Fargo & Company Has Lowered Expectations for Septerna (NASDAQ:SEPN) Stock Price

Septerna (NASDAQ:SEPN - Free Report) had its price target cut by Wells Fargo & Company from $14.00 to $11.00 in a research note released on Friday,Benzinga reports. They currently have an equal weight rating on the stock.

Separately, Cantor Fitzgerald restated an "overweight" rating and set a $50.00 target price on shares of Septerna in a report on Tuesday, February 11th.

Septerna Price Performance

Shares of NASDAQ:SEPN traded down $0.31 during trading on Friday, reaching $5.79. The stock had a trading volume of 374,511 shares, compared to its average volume of 461,932. The stock has a fifty day moving average of $9.96. Septerna has a 1-year low of $4.17 and a 1-year high of $28.99.

Septerna (NASDAQ:SEPN - Get Free Report) last released its earnings results on Thursday, March 27th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.69) by $0.05. The business had revenue of $0.21 million for the quarter, compared to analysts' expectations of $0.13 million. As a group, analysts expect that Septerna will post -7.11 earnings per share for the current year.

Remove Ads

Insider Activity at Septerna

In other news, CFO Gil M. Labrucherie purchased 5,000 shares of the firm's stock in a transaction on Friday, February 21st. The shares were bought at an average cost of $5.85 per share, for a total transaction of $29,250.00. Following the completion of the purchase, the chief financial officer now directly owns 30,000 shares of the company's stock, valued at approximately $175,500. This trade represents a 20.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Alan Ezekowitz bought 7,491 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The shares were purchased at an average cost of $6.35 per share, for a total transaction of $47,567.85. Following the purchase, the director now owns 24,911 shares in the company, valued at $158,184.85. This represents a 43.00 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 74,346 shares of company stock worth $439,670.

Institutional Trading of Septerna

A number of institutional investors and hedge funds have recently bought and sold shares of the business. RA Capital Management L.P. acquired a new position in shares of Septerna in the fourth quarter valued at approximately $160,205,000. TRV GP V LLC acquired a new position in shares of Septerna in the fourth quarter worth $142,337,000. TRV GP VI LLC acquired a new position in Septerna during the 4th quarter worth $72,191,000. Samsara BioCapital LLC purchased a new position in shares of Septerna in the 4th quarter valued at about $63,399,000. Finally, Driehaus Capital Management LLC acquired a new position in shares of Septerna during the fourth quarter worth about $59,301,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.